tbuckley/cabot-search huggingface dataset:
Accelerated partial-breast irradiation (APBI) versus whole-breast irradiation (WBI) in treatment of the biological subtypes of breast cancer: An analysis of comparative effectiveness.
Authors: Peter Y. Chen, Michelle Wallace, Hong Ye, Jessica Wobb, Maha Saada Jawad, Nayana Dekhne, Donald S. Brabbins
Journal: Journal of Clinical Oncology (2015)

45 Background: To assess if partial vs whole breast irradiation (RT) in treatment of the various biological (bio-) subtypes of breast cancer would lead to differing clinical results, a match pair analysis of APBI vs WBI was undertaken. Methods: Between 3/1993 and 9/2013 all breast CA patients (pts) treated at one institute with either APBI or WBI were matched 1:1 by follow-up (FU) +/- 15 yrs, stage and bio-subtype. This yielded 772 pts of whom 640 were luminal A, 42 luminal B, 58 triple neg (TNBC), 6 HER2+, and 26 triple +. Outcomes were analyzed across the various bio-subtypes for all the pts (APBI + WBI), APBI alone and WBI alone. The endpoints assessed were local recurrence (LR), true recurrence/marginal miss (TR/MM), elsewhere failure (EF), regional recurrence (RR), distant metastasis (DM), disease-free survival (DFS), and contralateral breast failure (CLBF). Results: Mean age was 66 (32-94) with a mean FU of 5.2 years (0.1-18.3). Regarding systemic therapy, 75% received endocrine Rx, while chemotherapy was documented in 21%. For all pts (APBI+WBI) there was no significant difference across the various bio-subtypes with respect to 5, 10 and 15 yr actuarial LR, TR/MM, EF, RR, DM, DFS and CLBF. Likewise, for the 386 APBI-alone treated pts, no significant difference was found between the various bio-subtypes for all the same endpoints reported. However, for the 386 WBI pts, a significant difference was seen in the 15-year actuarial LR between luminal A and TNBC (1.5% vs 7.4%, p = 0.007). Significance was also found in the 15-year actuarial DFS between luminal A/B and TNBC (98.0%, 95.2%; 86.0%, respectively, p = 0.009). Conclusions: In comparing partial to whole breast RT across the various biological subtypes of breast CA, APBI is at least as effective as WBI. However, the retrospective nature of this study along with the limited numbers of pts in the HER2+ and triple + subsets are weaknesses which are acknowledged to exist in this dataset. The addition of further pts in all the biological subtypes, particularly the HER2+ and triple + subsets, along with results from randomized trials incorporating biomarker data will be needed to substantiate these findings.
Outcome and Immune Reconstitution Following T Cell Depleted Nonmyeloablative Allogeneic Transplantation Using Matched Donors.
Authors: David A. Rizzieri, Liang Piu Koh, Gwynn D. Long, Cristina Gasparetto, Jerald Z. Gong, Anand S. Lagoo, Donna Niedzwiecki, Keith M. Sullivan, John Chute, Mitchell Horwitz, Morris Ashley, Nelson J. Chao
Journal: Blood (2005)
The clonal evolution of a breast tumor during neoadjuvant chemotherapy and metastasis
Authors: N.V. Litviakov, N. Cherdyntseva, M.K. Ibragimova, M. Tsyganov, A.V. Doroshenko, P. Kazantseva, J. Kzhyshkowska, E. Slonimskaya
Journal: Annals of Oncology (2016)
TMIC-29. DISTINCT MOLECULAR SIGNATURES OF MICROGLIA AND BONE-MARROW MACROPHAGES IN THE GLIOMA PERIVASCULAR NICHE
Authors: Soren Muller, Gary Kohanbash, Siyuan Liu, Diego Carrera, Manish Aghi, Daniel Lim, Hideho Okada, Aaron Diaz
Journal: Neuro-Oncology (2016)

Tumor associated macrophage (TAM) infiltration correlates with glioma grade and invasiveness. TAMs are comprised of brain-resident microglia and bone-marrow monocyte derived cells, which extravasate the blood-brain barrier. Study of the distinct roles of these two populations of TAMs has been confounded by their overlapping and inducible gene expression profiles. To identify durable and specific gene-expression signatures for TAMs of microglial and bone-marrow origin respectively, we profiled regional biopsies of primary, untreated gliomas using single-cell and bulk sequencing. In 4 glioblastomas and 2 low-grade gliomas, we single-cell mRNA sequenced 672 TAMs from regional biopsies of the infiltrated white matter, the enhancing edge, and the tumor core. Exome-sequencing was also performed on bulk DNA-extractions from each biopsy, and matched blood. Additionally, we single-cell sequenced microglia derived from non-malignant human neocortex and we reanalyzed single-cell and bulk mRNA sequencing data of microglia and bone-marrow macrophages in human and mouse. Based on this, we identified a signature of specific purinergic receptors and other genes that is: 1) differentially expressed between non-malignant microglia and bone-marrow macrophages, across multiple samples and ages; 2) correlated with CX3CR1 and CD11b expression in TAMs extracted from patient biopsies at the mRNA and protein level; 3) enriched in the infiltrated white matter; 4) is conserved in mouse. A pro-angiogenic expression profile specific to putative bone-marrow TAMs, including VEGF and other genes, correlates with lymphotoxin beta receptor expression in patient biopsies and can be attenuated through lymphotoxin inhibition in in vitro, explant experiments.
Clinical Characteristics, Immediate Treatment, and Long-Term Management of Venom Allergic Reactions Presenting to Canadian Pediatric Emergency Departments and out-of-Hospital Emergency Services
Authors: Lea K. Restivo, Ann E. Clarke, Jocelyn Moissan, Harley Eisman, Judy Morris, Edmond S. Chan, Greg Shand, Moshe Ben-Shoshan
Journal: Journal of Allergy and Clinical Immunology (2017)
Abstract 030: Cardiac-specific Expression Of Constitutively Active Sumo-2 In Mice Leads To Cardiomyopathy
Authors: Eun Y Kim, Yu Wei, Qian Ling, Jiang Chang, Yutao Xi, Jun Wang
Journal: Circulation Research (2013)

Sumoylation is a versatile posttranslational modification that regulates a wide spectrum of cellular activities and is involved in a number of human diseases. Cardiomyopathy is the leading cause of heart failure. Whether and how sumoylation is implicated in cardiomyopathy has not been well investigated. To address this issue, we generated a number of independent transgenic mouse lines that express constitutively active SUMO-2 in hearts (SUMO-2-Tg). Four of five SUMO-2-Tg mouse lines exhibited cardiomyopathy with various severities, ranging from acute heart failure leading to early death to hypertrophic cardiomyopathy which developed gradually as mice aged. An increase in apoptosis was observed in the SUMO-2-Tg hearts prior to the occurrence of any other discernible heart phenotypes. Adenovirus-mediated expression of SUMO-2 in cultured cardiomyocytes significantly increased Annexin V staining, indicating that SUMO-2 directly promoted the apoptotic process. We further revealed that SUMO-2 was directly involved in regulation of apoptosis at least partially via targeting calpain 2 (Capn2) and its natural inhibitor calpastatin (CAST). SUMO attachment to CAST mainly promoted its turnover, thus inhibiting CAST activity. On the other hand, SUMO-2 linkage to Capn2 increased its capacity to promote apoptosis, as evidenced by the observation that adenovirus-aided expression of SUMO-fused Capn2 (SUMO-Capn2) in cultured cardiomyocytes significantly promoted Annexin V staining compared with free Capn2. We also observed that SUMO-2/3 conjugation was significantly increased in the human failing hearts compared with the control hearts. Correspondingly, elevated levels of SUMO-2/3-conjugated Capn2 and CAST were detected in the human failing hearts vs. control hearts. Thus, elevated SUMO-2 conjugation led to increased apoptosis and cardiomyopathy at least partially via targeting calpain-calpastatin proteolytic system. The present study uncovers a direct regulation of the apoptotic pathway by the SUMO-2/3 conjugation pathway.
Prolonged Survival of Lymphoma Patients Achieving Complete Remission Following High-Dose Sequential Chemotherapy and Autograft (HDS Program): A GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) Retrospective Study on 1,266 Patients.
Authors: Corrado Tarella, Manuela Zanni, Alessandro Rambaldi, Michele Magni, Marco Sorio, Roberto Passera, Caterina Patti, Fabio Ciceri, Andrea Gallamini, Sergio Cortelazzo, Ignazio Majolino, Salvatore Mirto, Mario Boccadoro, Paolo Corradini, Fabio Benedetti, Tiziano Barbui, Alessandro M. Gianni
Journal: Blood (2006)
Impact of Parental Donor Type On Outcomes After HLA-Matched and HLA-Mismatched T-Cell-Replete Hematopoietic Cell Transplantation for Patients with Leukemia: A Retrospective Cohort Study.
Authors: Tatsuo Ichinohe, Junya Kanda, Jiro Inagaki, Masami Inoue, Katsuyoshi Koh, Atsushi Kikuta, Hiromasa Yabe, Junji Tanaka, Yoshiko Atsuta, Yoshinobu Kanda
Journal: Blood (2012)
Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluiting Beads (DEBIRI) in Refractory Liver Colorectal Cancer Metastases: a phase II study
Authors: G. Ranieri, I. Marech, C. Altini, V. Fazio, L. Caporusso, G. Vinciarelli, M. Porcelli, F. Macina, D. de Ceglia, M. Ammendola, F. Armenise, G. Rubini, C.D. Gadaleta
Journal: Annals of Oncology (2016)
10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents
Authors: Anders M. Galløe, Henning Kelbæk, Leif Thuesen, Henrik S. Hansen, Jan Ravkilde, Peter R. Hansen, Evald H. Christiansen, Ulrik Abildgaard, Ghita Stephansen, Jens F. Lassen, Thomas Engstrøm, Jan Skov Jensen, Jørgen L. Jeppesen, Niels Bligaard, Niels Bligaard, Leif Thuesen, Henning Kelbæk, Per Thayssen, Jens Aarøe, Peter R. Hansen, Jens F. Lassen, Kari Saunamäki, Anders Junker, Jan Ravkilde, Ulrik Abildgaard, Hans H. Tilsted, Thomas Engstrøm, Jan S. Jensen, Hans E. Bøtker, Søren Galatius, Carsten T. Larsen, Steen D. Kristensen, Lars R. Krusell, Steen Z. Abildstrøm, Evald H. Christiansen, Michael Meng, Lisette Okkels, Ghita Stephansen, Jørgen L. Jeppesen, Anders M. Galløe
Journal: Journal of the American College of Cardiology (2017)
Clinical and Biological Characterization of Children with FLT3ITD Mutated Acute Myeloid Leukemia (AML): A Report from the AIEOP AML-2002 Study Group
Authors: Elena Manara, Valeria Bisio, Marco Frison, Katia Polato, Claudia Tregnago, Barbara Buldini, Riccardo Masetti, Roberto Rondelli, Gianni Cazzaniga, Andrea Biondi, Franco Locatelli, Martina Pigazzi, Giuseppe Basso
Journal: Blood (2015)
Final Results of the HERACLES trial in HER2 amplified colorectal cancer
Authors: S. Siena, A. Sartore-Bianchi, L. Trusolino, C. Martino, K. Bencardino, S. Lonardi, V. Zagonel, F. Leone, E. Martinelli, F. Ciardiello, P. Racca, A. Amatu, L. Palmeri, E. Valtorta, A. Cassingena, A. Vanzulli, D. Regge, S. Veronese, A. Bardelli, S. Marsoni
Journal: Annals of Oncology (2016)
470P Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma
Authors: C.S. Chai, C.K. Liam, Y.K. Pang, K.S. Kow, C.K. Wong, M.E. Poh, J.L. Tan
Journal: Annals of Oncology (2016)
EVI1 Blocks Apoptosis in DA-1 Myeloid Leukemia Cells Via Enhanced Transcription of the Prosurvival Gene Bcl2a1 (A1)
Authors: Archibald S. Perkins, Jacob J. del Campo, Ying-Yi Xiao, Yi Zhang, Sharon J. Lin, Jonathan Dudley, David Tuck, Bogdan Yatsula
Journal: Blood (2008)
Predictive Accuracy Of Peanut Components In The Diagnosis Of Peanut Allergy: A Systematic Literature Review And Meta-Analysis
Authors: Malin Berthold, Barbara Mascialino, Donna Fountain, Kevin Cadwell, Chrysanthi Papageorgakopoulou, Sigrid Sjolander, Robert G. Hamilton
Journal: Journal of Allergy and Clinical Immunology (2017)
Prognostic and diagnostic significance of epigenetic alterations of p16 and DAPK1 promoter sequences in patients with epithelial ovarian carcinoma (EOC).
Authors: Ab Rashid Mir, Imtiyaz Ahmad Najar, Prasant Yadav, Jamsheed Javed, Mariyam Zubari, Shazia Farooq, Gauri Gandhi, Prakash C. Ray, Sagar Dholariya, Alpana Saxnena
Journal: Journal of Clinical Oncology (2012)

62 Background: Novel strategies for early detection of EOC, the most common and second most lethal cancer in Indian women, are urgently needed. Silencing tumor suppressor genes via DNA methylation has established hypermethylation as one of the most frequent molecular alterations that may initiate and drive many types of human neoplasia including EOC. To determine the alterations of tumor suppressor gene DAPK1 and p16INK4A in EOC patients to explore the possibilities of identifying potential minimally invasive markers in blood of the patients, which could help in the clinical practice as a diagnostic and prognostic marker. Methods: Fifty EOC patients with primary epithelial ovarian cancer were selected for the study; these patients were followed for a median of 20 months. Genomic DNA extracted from fresh peripheral blood and serum followed by sodium bisulfate modification. The DAPK1 and p16 methylation was detected using methylation-specific PCR (MSP). The DAPK1 and p16 methylation status was correlated with age, stage,menopause, Ca125.5 and clinic pathological features. Results: The frequencies of DAPK1 and p16 methylation in EOC patients was found to be 68% and 84% respectively . Aberrant methylation of DAPK1 and p16 was associated with age at diagnosis (p = 0.043) .The significant association was seen with age,menopause. Patients with high methylation indices had poor prognosis (p&lt;0.001, Hazards ratio=14.58) with age (p = 0.043), and tumor stage (p = 0.033). Aberrant methylation of DAPK1 and p16 was strongly associated with EOC patients (p = 0.037 respectively). Conclusions: our results that the methylated loci of TSGs (DAPK1 and p16) may be employed as clinically useful biomarkers for prognosis and diagnosis of EOC noninvasively using readily available body fluid by MS-PCR and proved to be efficient and cost-effective method.
Utilization of sperm banking in men undergoing chemotherapy for testis cancer.
Authors: Mary J. Brames, Lawrence H. Einhorn, Somer Case-Eads, Daniel Sonnenburg
Journal: Journal of Clinical Oncology (2016)

122 Background: Testicular cancer is the most common carcinoma in men ages 18-35. Eighty percent of patients with metastatic disease will be cured with cisplatin based chemotherapy. However, approximately 40% of patients receiving chemotherapy will have permanent azospermia or oligospermia, impairing future fertility. Sperm banking prior to chemotherapy is an effective method of maintaining fertility. This retrospective study was performed to assess utilization and results from sperm banking, as well as the barriers to its use. Methods: Patients 18 and older who were 1-year post chemotherapy were given a 5-item questionnaire on follow-up visit. The questionnaire included a mix of quantitative and qualitative questions. Results: 200 patients with metastatic testicular cancer including patients who started initial chemotherapy at other institutions, enrolled in the study and all completed the questionnaire. 139/200 (70%) chose not to bank sperm: 71 (51%) of those were not interested, 25 (18%) declined due to desire to start immediate chemotherapy, 24 (17%) were not offered, 6% of those not offered were from Indiana University, 12 (9%) declined due to cost, and 7 (5%) answered "other". The average age at cancer diagnosis of patients who banked sperm was 28.4 as opposed to 32.6 for patients who did not bank sperm (p = 0.003). The percentage of patients who had children before their diagnosis was 21% in the sperm banking group and 50% in the group that did not (p = 0.0002). Sixty-one (30%) chose to bank sperm, 11 of 61 patients (18%) utilized the banked sperm. 9 of 11 (82%) that utilized the banked sperm resulted in successful paternity: 3 of 9 (33%) produced twins. There were no birth defects. Conclusions: Sperm banking provides the opportunity for paternity in testicular cancer patients. However, the majority of these patients chose not to bank sperm or was not offered the opportunity. A range of factors such as time, emotional state, patient age, disease stage, prior children, institutional practices, and cost all influence whether sperm banking is offered and taken up. Physicians and patients need to be aware of the potential benefit of sperm banking.
Aberrant Expression of Golgin-84 in Non-Hodgkin Lymphomas and Plasma Cell Myeloma
Authors: Ling Chen, Yaling Yang, C. Cameron Yin, Gary Lu, Su Chen, Xiaoyan Huang, Jiayu Chen, Felix Chang, Effie Rahman, Steliana Calin, L. Jeffrey Medeiros, Roberto N. Miranda, M. James You
Journal: Blood (2011)
A molecular census of arcuate hypothalamus and median eminence cell types
Authors: John N Campbell, Evan Z Macosko, Henning Fenselau, Tune H Pers, Anna Lyubetskaya, Danielle Tenen, Melissa Goldman, Anne M J Verstegen, Jon M Resch, Steven A McCarroll, Evan D Rosen, Bradford B Lowell, Linus T Tsai
Journal: Nature Neuroscience (2017)
PROPERTIES OF THE CAUSATIVE AGENT OF A CHICKEN TUMOR
Authors: Ernest Sturm, Frederick L. Gates, James B. Murphy
Journal: The Journal of Experimental Medicine (1932)

Even though part of the energy of the incident light is probably absorbed by chemical entities which play no part in the specific reaction of inactivation, nevertheless the wave lengths most active in destroying biological cells or agents will presumably be found to be among those absorbed in the highest proportion. This would indicate that the curves here presented are approximately reciprocal to the coefficients of absorption of particular substances, the destruction of which caused the inactivation of the agents or the death of the cells. The similarity between the curves for bacteria, virus, and phage, both in shape and in total involved energies, suggests the presence of a common factor, or of closely related chemical entities, sensitive to ultra-violet light, whereas the data for the tumor agent suggest that its inactivation is due to the destruction of a substance having an essentially different spectral absorption, and therefore of a different chemical character. While the amount of ultra-violet energy required to affect the tumor agent is great, it is still less than that involved in the inactivation of some of the enzymes (7). A study is under way to compare the deduced spectral analysis with the actual coefficients of absorption of the highly purified tumor agent.
First-line triplet or doublet chemotherapy for advanced gastric cancer: Analysis of 970 patients from a community practice registry
Authors: I. Echavarria Diaz-Guardamino, A. Carmona-Bayonas, P. Jimenez Fonseca, A.J. Muñoz Martin, M.L. Sanchez Lorenzo, A. Custodio, M. Garrido, J.M. Cano, J.E. Lorenzo Barreto, A. Lacalle, M. Ferrer Cardona, M. Manga, L. Visa, E. Buxo, A. Azkarate, A. Diaz, A. Ramchandani, M. Mugica, P. Sala, P. García Alfonso
Journal: Annals of Oncology (2016)
High-Dose Etoposide with Granulocyte Colony-Stimulating Factor for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Hematologic Malignancies.
Authors: Xiao-yan Zhang, Jianyong Li, Sixuan Qian, Hongxia Qiu, Han-xin Wu, Hua Lu, Wei Xu, Ming Hong
Journal: Blood (2009)
Modeling fecal incontinence symptoms 6 years after high-dose radiation for prostate cancer: Clinical and dosimetric predictors.
Authors: Giovanni Fellin, Tiziana Rancati, Claudio Fiorino, Vittorio Vavassori, Emanuela Cagna, FloraAnna Mauro, Giuseppe Malinverni, Riccardo Valdagni
Journal: Journal of Clinical Oncology (2012)

71 Background: To evaluate the incidence of late fecal incontinence (linc) after high-dose radiotherapy (RT) in prostate cancer patients (pts) accrued in AIROPROS 0102 trial (RT doses: 70-80Gy, 1.8-2Gy/fr) and to model the relationship between linc and clinical/dosimetric factors. Methods: Self-reported questionnaires of 515 pts with a minimum follow up of 6 yrs were analyzed with respect to linc. G1 linc was scored if unintentional stool discharge was “sometimes” experienced, G2 linc if unintentional stool discharge was “often” experienced or if pts sporadically used sanitary pads; G3 if pts reported daily unintentional stool discharge or use of sanitary pad &gt;2 times/week. Correlation between pre-treatment morbidities, hormonal therapy, drug prescription, presence of diabetes or hypertension, abdominal surgery prior to RT (SURG), presence of G2-G3 acute fecal incontinence (ACUINC), pelvic nodes and seminal vesicles irradiation, mean rectal dose, dose-volume histograms constraints (from V20Gy to V75Gy) and linc was investigated by uni- and multivariate (MVA) logistic analyses. 347/515 pts had at least 3 toxicity questionnaires in the first 36 mos after the end of RT. Correlation between the mean score of fecal incontinence in the first 36 mos and linc at 6 yrs was also investigated. Results: 50/515 G1, 3/515 G2 and 3/515 G3 linc were reported. In MVA, V40Gy (continuous variable, p=0.09, OR=1.015), use of antihypertensives (protective factors, p=0.005, OR=0.38), SURG (p=0.004, OR=4.7), presence of haemorrhoids (p=0.008, OR=2.6) and ACUINC (p=0.007, OR=4.4) resulted to be correlated to linc. Based on MVA results, a nomogram was developed. Linc at 6 yrs was also correlated to the mean incontinence scores in the first 36 mos (p&lt;0.0001): pts without linc at 6 yrs had a mean score of 0.1 during the first 36 mos, while pts with G1 and with G2-G3 linc at 6 yrs had a mean score of 0.5 and 0.78 during the first 36 mos, respectively. Conclusions: Mean score for incontinence during the first 36 mos after RT can be used as a surrogate endpoint for late (&gt;6yrs) fecal incontinence. Linc is correlated to clinical and dosimetric risk factors and individualised toxicity prediction can be performed through a nomogram.
Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)
Authors: Sudhir Gupta, Mark R. Stein, Isaac Reuven Melamed, Iftikhar Hussain, Kenneth Paris, Werner Engl, Barbara McCoy, Christopher J. Rabbat, Leman Yel
Journal: Journal of Allergy and Clinical Immunology (2017)
Correlation of body mass index with female survival benefit among a single-institution cohort of cutaneous melanomas &gt;1 mm thick following wide-local excision and sentinel lymph node biopsy.
Authors: Laura K. Jackson, Kaleigh Joy Bulloch, Deepak Narayan, Stephan Ariyan, Bonnie Elyssa Gould Rothberg
Journal: Journal of Clinical Oncology (2016)

172 Background: As the 10-year mortality for localized cutaneous melanomas (CMMs) &gt; 1.00 mm is 40%, non-therapeutic interventions to supplement active surveillance following resection may be beneficial. Data describing the impact of lifestyle choices on survival in this population are limited. Methods: 837 consecutive patients who underwent wide local excision and sentinel lymph node biopsy (WLE + SLNB) at Yale during 1997-2012 for CMMs &gt; 1.00 mm thick were enrolled. Smoking, alcohol use and caffeine consumption were assessed by questionnaire at diagnosis and were each categorized according to quantity used with never-users as the reference. Body mass index (BMI) was calculated from height and weight measured at surgery. Crude and multivariable marginal relationships between lifestyle factors and disease free survival (DFS), the latter adjusted for age, sex, thickness (mm), ulceration, mitotic count, and SLN status, were assessed using Cox proportional hazards. Interactions with clinicopathologic factors were conducted. Results: A female survival benefit (HR FEMALE = 0.69; 95% CI: 0.49-0.97; p = 0.04) was observed on multivariable analysis. While BMI was not independently associated with DFS (p = 0.31), we noted a significant interaction between sex and BMI (p = 0.01). Compared with referent normal weight (BMI &lt; 25) men, normal weight women had similar survival (HR BMI &lt; 25 = 0.91; 95% CI: 0.52-1.57, p = 0.74) but a progressive survival advantage was observed among women with increasing BMI (HR OVERWT = 0.62; 95% CI: 0.33-1.14, HR OBESE = 0.23; 95% CI: 0.07-0.58, p trend = 0.01). A similar relationship was not observed among men (p trend = 0.51). Neither the marginal effects nor those modified by sex for each of alcohol, tobacco or caffeine were associated with DFS (p &gt; 0.15). Conclusions: Following WLE+SLNB, increasing BMI may improve survival among women but not among men. Research to identify contributory molecular mechanisms in the context of the female survival benefit is warranted.